Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Primary Indications
* **Acute Coronary Syndrome (ACS):** Treatment of ACS, including patients who are managed medically and those who are to be treated with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).
* **History of Myocardial Infarction (MI):** In patients with a history of MI (at least 6 months prior to treatment initiation) and at high risk for a subsequent ischemic event, to reduce the rate of thrombotic cardiovascular events.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily.
* *Consideration:* For patients undergoing PCI, a 180 mg loading dose is recommended. Some guidelines may suggest continuing 90 mg twice daily for at least 12 months. Therapy duration may be individualized based on bleeding risk, recurrent ischemic event risk, and local protocols.
* **History of MI (at least 6 months prior):**
* **Maintenance Dose:** 60 mg orally twice daily.
* *Consideration:* Therapy duration is typically 12 months, or until the patient is no longer at high risk for a subsequent ischemic event, but should not exceed 30 months.
## Pediatric Dosing
Ticagrelor is not recommended for use in pediatric patients due to a lack of data.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is needed in patients with mild to moderate hepatic impairment. Use with caution in severe hepatic impairment due to lack of data.
* **Renal Impairment:** No dose adjustment is needed in patients with mild to moderate renal impairment. Use with caution in severe renal impairment due to lack of data.
## Contraindications
* Known hypersensitivity to ticagrelor or any of its excipients.
* Active pathological bleeding.
* History of intracranial hemorrhage.
## Adverse Effects
* **Common:** Dyspnea, bradycardia, diarrhea, contusion, rash.
* **Serious:** Bleeding (major, minor, life-threatening), ventricular pauses, increased serum creatinine, hyperuricemia.
* **Bleeding:** Increased risk of bleeding, including fatal and life-threatening bleeding. Risk factors include age, concomitant anticoagulant therapy, prior bleeding, and renal or hepatic impairment.
* **Dyspnea:** Typically mild and transient, may resolve with continued therapy.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor exposure.
* **CYP3A4 Substrates:** Concomitant use with strong CYP3A4 substrates (e.g., simvastatin, atorvastatin) may increase exposure to the substrate.
* **P-glycoprotein (P-gp) Substrates:** Ticagrelor is a P-gp inhibitor. Concomitant use with P-gp substrates (e.g., digoxin) may increase their exposure.
* **Aspirin:** Generally used in combination with aspirin. Dose of aspirin greater than 100 mg may increase bleeding risk and reduce ticagrelor's efficacy.
* **Anticoagulants:** Increased risk of bleeding. Concomitant use should be undertaken with caution and is generally not recommended unless clinically indicated.
* **NSAIDs:** Increased risk of bleeding.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding.
* **Renal Function:** Monitor serum creatinine and electrolytes, particularly in patients with renal impairment or those on other nephrotoxic agents.
* **Cardiac Rhythm:** Monitor for bradycardia, especially in patients with risk factors.
## Clinical Pearls
* The 180 mg loading dose in ACS is crucial for rapid platelet inhibition.
* For patients with a history of MI, the 60 mg twice daily dose is used. This indication is for secondary prevention in high-risk patients.
* Discontinuation of ticagrelor may lead to an increased risk of thrombotic events. If discontinuation is necessary, consider a brief washout period if transitioning to another P2Y12 inhibitor.
* Dyspnea is a common side effect, often manageable and does not necessarily indicate underlying cardiac pathology.
***
*This information is intended for healthcare professionals and does not replace clinical judgment. Always verify current prescribing information and consult relevant guidelines before initiating or modifying therapy.*
